Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Vedolizumab wins the long game in UC treatment. A large Swedish cohort study found that ulcerative colitis patients who started on vedolizumab spent more time in corticosteroid-free disease stability compared to those on adalimumab or infliximab — roughly 3 to 5 extra steroid-free months over 5 years. Hospitalization and colectomy rates were similar across all three biologics.
Vedolizumab may have an edge over TNF antagonists when it comes to keeping ulcerative colitis (UC) patients stable long-term — but it's not a landslide victory. A population-based cohort study published in JAMA Network Open analyzed data from 3,263 biologic-naive patients in Sweden with moderate-to-severe UC, tracking outcomes over a median follow-up of 4.3 to 5.4 years.
Patients who initiated vedolizumab spent a greater proportion of their follow-up time in corticosteroid-free disease stability compared to those who started on either infliximab or adalimumab. Adalimumab starters also switched therapies more frequently than vedolizumab initiators. That said, rates of hospitalization and colectomy were comparable across all three biologics — leading researchers to describe the advantage as "a tiebreaker, not a knockout."
By the Numbers:
Why it matters: For clinicians choosing a first-line biologic in UC, these findings shift the conversation from short-term remission to long-term disease management. When no compelling reason exists to favor a TNF antagonist, this data supports starting with vedolizumab — and raises the bigger question: which sequence of therapies best serves each patient over a decade?